Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
20.02
+0.80 (4.14%)
May 3, 2024, 9:33 AM EDT - Market open
Myriad Genetics Revenue
In the year 2023, Myriad Genetics had annual revenue of $753.20M with 11.03% growth. Revenue in the quarter ending December 31, 2023 was $196.60M with 10.57% year-over-year growth.
Revenue (ttm)
$753.20M
Revenue Growth
+11.03%
P/S Ratio
2.29
Revenue / Employee
$278,963
Employees
2,700
Market Cap
1.79B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
Dec 31, 2021 | 690.60M | 52.00M | 8.14% |
Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
Jun 30, 2019 | 851.10M | 107.40M | 14.44% |
Jun 30, 2018 | 743.70M | 15.00M | 2.06% |
Jun 30, 2017 | 728.70M | -11.80M | -1.59% |
Jun 30, 2016 | 740.50M | 17.40M | 2.41% |
Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
Jun 30, 2005 | 82.41M | 25.76M | 45.47% |
Jun 30, 2004 | 56.65M | -7.67M | -11.93% |
Jun 30, 2003 | 64.32M | 10.49M | 19.48% |
Jun 30, 2002 | 53.84M | 8.67M | 19.21% |
Jun 30, 2001 | 45.16M | 11.15M | 32.78% |
Jun 30, 2000 | 34.01M | 8.70M | 34.37% |
Jun 30, 1999 | 25.31M | 2.10M | 9.06% |
Jun 30, 1998 | 23.21M | 7.97M | 52.34% |
Jun 30, 1997 | 15.24M | 8.61M | 129.85% |
Jun 30, 1996 | 6.63M | 5.33M | 412.06% |
Jun 30, 1995 | 1.29M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.39B |
Harmony Biosciences Holdings | 617.51M |
NeoGenomics | 610.66M |
Supernus Pharmaceuticals | 607.52M |
Alphatec Holdings | 482.26M |
Catalyst Pharmaceuticals | 398.20M |
Beam Therapeutics | 377.71M |
Twist Bioscience | 262.36M |
MYGN News
- 2 days ago - Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 16 days ago - Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor - GlobeNewsWire
- 17 days ago - New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen - GlobeNewsWire
- 24 days ago - Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device - GlobeNewsWire
- 2 months ago - Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance - GlobeNewsWire
- 2 months ago - Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 - GlobeNewsWire